Dynastat

Selected form

Parecoxib

Method of action: Anti-Inflammatory, Pain Reliever

Treatment option: Pain, Postoperative Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dynastat

Property	Description
Active ingredient	Parecoxib sodium
Form	Lyophilized powder for solution for injection
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Acute pain management
Origin	Synthetic (Chemically synthesized)

Dynastat is a potent, synthetic, prescription-only injectable medicine whose active component is Parecoxib sodium, and it is classified within the broad family of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This medication is specifically identified as a selective Cyclooxygenase-2 (COX-2) inhibitor, a subtype of NSAIDs dedicated to targeted pain relief. Parecoxib is utilized as an effective post-operative analgesic for adults undergoing surgical procedures.

What Type of Medicine is Dynastat (Parecoxib)?

Dynastat is a synthetic, single-ingredient product classified as a selective Non-Steroidal Anti-Inflammatory Drug (NSAID), belonging to the chemical subgroup known as the coxibs. Its distinction lies in its mechanism, which predominantly inhibits the Cyclooxygenase-2 enzyme, clinically recognized for its role in mediating inflammation and pain. This enzyme is primarily induced at sites of injury, where it produces the chemical messengers called prostaglandins that directly cause pain and swelling. The drug’s focused action establishes its utility in therapeutic settings requiring rapid and effective pain control, particularly where minimizing broad-spectrum anti-inflammatory effects is desired.

Composition and The Function of Parecoxib as a Prodrug

The core component of the medicine is Parecoxib sodium, which is supplied as a sterile, lyophilized powder for solution for injection. Notably, Parecoxib is designed as a prodrug; the administered compound is initially chemically inactive and requires the body to rapidly convert it into the potent, active therapeutic agent, valdecoxib. This biotransformation ensures the drug delivers its pain-relieving effect rapidly following parenteral administration via injection, which is essential for patients unable to take oral medication. The prodrug design enables the quick generation of the active substance in the bloodstream, facilitating rapid pain relief.

General Purpose: Acute Pain Management

The general purpose of administering Dynastat is to achieve fast-acting, effective analgesia and an anti-inflammatory effect when treating intense, sudden discomfort, such as recovery following major surgery. By selectively blocking the COX-2 enzyme, the medication interrupts the synthesis of pro-inflammatory prostaglandins, thereby providing relief from acute pain. Its utility is dedicated to providing robust, immediate pain management, particularly in structured clinical environments where its injectable form and rapid onset of action are key differentiating factors.

Regulatory References

EMA Product Information

What side effects are possible with Dynastat?

Possible Side Effects and Safety Information

The safety profile for Dynastat (parecoxib) is classified and documented by governmental regulatory authorities based on observed adverse reactions. These effects are grouped by the physiological system affected and by their frequency of occurrence.

Adverse Reaction Classifications

Side effects are categorized based on their incidence in clinical studies. Common reactions (occurring in 1 to 10 out of 100 people) include nausea, headache, dizziness, postoperative edema (fluid retention), and injection site pain. Less frequently observed effects are classified as uncommon or rare.

Serious Adverse Reactions

The most serious documented safety concerns relate to two organ systems. Like other selective NSAIDs, this medicine is associated with a risk of serious cardiovascular (CV) thrombotic events, such as myocardial infarction (heart attack) and stroke. The official labeling also highlights the risk of serious gastrointestinal events, including ulceration, bleeding, and perforation of the stomach or intestines. Rare but severe hypersensitivity reactions (e.g., anaphylaxis) and serious skin reactions (e.g., Stevens-Johnson Syndrome) are also noted.

Safety Considerations and Restrictions

The risk of cardiovascular events is officially noted to increase with the duration of use. The medicine is contraindicated in certain patient populations, including those with severe congestive heart failure or active gastrointestinal bleeding or ulceration. Furthermore, official regulatory documents state that the drug should not be used for pain following Coronary Artery Bypass Graft (CABG) surgery or in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Dynastat (Parecoxib sodium) indicates that clinical experience with a specific overdose of this medicine is limited. Overdose information is primarily based on common adverse reactions observed at high doses and the known toxicity of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.

Overdose Scope: Official Regulatory Information

Domain	Regulatory Statement
Documented overdose presentations	Overdose reports have been associated with common adverse reactions, including nausea, stomach pains, tiredness, and drowsiness.
Physiological systems affected	The profile identifies a risk of serious gastrointestinal (GI) complications (perforations, ulcers, bleeding) and acute renal deterioration as severe outcomes associated with high exposure to the NSAID class.
Dose-related factors	Overdose information is based on the toxicity profiles of the NSAID class at higher-than-recommended exposure levels.
Population-specific overdose notes	Patients with moderate hepatic impairment or elderly patients weighing less than 50 kg require dosage consideration, reflecting a heightened potential for adverse events.
Emergency-response statements	No specific antidote is known. Management consists of symptomatic and supportive treatment.
When immediate medical help is required	Patients must seek urgent medical attention if there is any suspicion of receiving an excessive dose.

Overdose Classifications (High-Level)

Classification Aspect	Regulatory Basis
Severity classification	Overdose has the potential to lead to serious adverse outcomes, including fatal GI complications and acute renal deterioration.
Overdose-context constraints	Clinical experience with specific Parecoxib overdose is limited; the profile relies on adverse reactions and general NSAID toxicity.

The regulatory documentation defines the overdose profile primarily through common adverse events seen at high doses and the severe complication risks inherent to the entire NSAID class. This structure necessitates that, as no specific antidote is available, patients must immediately seek urgent medical attention to ensure necessary supportive treatment and monitoring for potentially life-threatening complications are provided.

Therapeutic Uses of Dynastat

What Dynastat Treats: Main Uses and Benefits

This injectable medication is generally used for the short-term symptomatic support of intense, sudden discomfort in adults, primarily applied when symptoms related to physical discomfort (moderate to severe acute pain) arise from tissue injury. This medicine is commonly used to help with short-term pain relief following an operation. It contributes to relief that helps patients cope more steadily during difficult recovery phases.

The therapeutic support is primarily focused on postoperative pain control and the management of associated inflammatory states. The medicine is relevant in clinical settings for conditions that involve acute, disruptive episodes, such as orthopedic, abdominal, and gynecological operations. Its strategic use offers symptomatic assistance that can generally help reduce the patient's requirement for or consumption of opioid pain medications, assisting with maintaining functional stability during recovery.

“The medication is applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Acute Postoperative Discomfort

This medicine is a relevant non-opioid component in multimodal analgesia, often used when symptoms intensify and supportive relief is needed to ease the overall symptom load following surgery.

Regulatory References

European Medicines Agency

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dynastat

Dynastat (parecoxib) is reserved for adults 18 years and older. Its use is not recommended in the paediatric population as safety and efficacy have not been established by regulatory authorities.

Populations for whom use is Contraindicated

Absolute prohibition applies to several groups, including:

Patients with a known allergy to Parecoxib, its active metabolite valdecoxib, sulfonamide medicines, or any patient who has experienced allergic reactions like bronchospasm after taking aspirin or other NSAIDs.
Patients immediately following Coronary Artery Bypass Graft (CABG) surgery.
Patients with active peptic ulceration, gastrointestinal (GI) bleeding, inflammatory bowel disease, or severe congestive heart failure (NYHA Class II–IV).
Women in the third trimester of pregnancy or who are breastfeeding.
Patients with severe hepatic impairment (Child-Pugh score ge 10).

Eligibility-Related Restrictions (Conditional Use)

Some populations require strict caution and monitoring:

Patients with moderate hepatic impairment (Child-Pugh score 7–9) must be introduced at a reduced maximum daily dose.
Patients with severe renal impairment must be initiated at the lowest recommended dose with close kidney function monitoring.
Elderly female patients weighing < 50 kg should also start treatment with a reduced dose.

The regulatory documentation classifies populations as contraindicated, not recommended, or subject to conditional use, strictly defining the boundaries for who can and cannot be administered the medicine.

What should I know about interactions with other medicines?

The official regulatory documents specify several pharmacodynamic and pharmacokinetic interactions for Dynastat, Parecoxib sodium.

Pharmacodynamic Interactions

Co-administration with oral anticoagulants (e.g., Warfarin, Apixaban) and antiplatelet agents (including Acetylsalicylic Acid) is associated with an increased risk of bleeding and gastrointestinal complications. This risk is formally documented across regulatory sources.

Combining Parecoxib with Diuretics or ACE Inhibitors/Angiotensin-II Antagonists may increase the risk of renal function deterioration and may counteract the blood pressure-lowering effects of these medications.

Pharmacokinetic and Population-Specific Notes

The metabolism of the active drug, Valdecoxib, is primarily mediated by the CYP2C9 enzyme pathway. Co-administration with CYP2C9 inhibitors (such as Fluconazole) is documented to increase the plasma concentration of Valdecoxib.

Use is contraindicated in patients with severe hepatic impairment (Child-Pugh score 10), as compromised clearance leads to significantly increased systemic exposure to the active drug.

Product Restrictions

The concomitant use of Parecoxib with other Non-Acetylsalicylic Acid NSAIDs, including other COX-2 inhibitors, must be avoided. Procedurally, the lyophilized powder must not be mixed with any other medicinal product during reconstitution or injection due to the risk of precipitation. Specific fluids, such as Lactated Ringer's or 5% Glucose in Lactated Ringer's, are explicitly not recommended for reconstitution.

Mechanism of Action

Prodrug Activation and Selective COX-2 Targeting

The medicine is supplied as the inactive Parecoxib prodrug, which is quickly and completely converted by hepatic carboxylesterases (liver enzymes) into its pharmacologically active form, Valdecoxib. This active metabolite then functions as a highly selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This rapid activation mechanism governs the short duration required for initiation of biological target inhibition following administration.

Suppression of Prostaglandin Signaling Cascade

The core mechanism involves blocking the COX-2 enzyme, which is primarily induced during states of heightened physiological activity. By inhibiting COX-2, the drug drastically reduces the synthesis of pro-inflammatory messengers like Prostaglandin E2 ( PGE2), a chemical that promotes nociceptor sensitization. This process directly suppresses the Arachidonic Acid Cascade at the site of activation. The reduction of PGE2 levels at peripheral tissues limits the chemical sensitization of nociceptors (pain receptors), thereby reducing the level of afferent input to the central nervous system, and results in lowered inflammatory exudation.

Dosage and Administration Information

How to Use Dynastat

The usage of Dynastat (Parecoxib) focuses on parenteral administration for short-term pain management. The medicine is supplied as a lyophilized powder for solution for injection.

Administration and Dosing

Feature	Official Usage Principle
Route of Administration	Strictly Intravenous (IV) or Intramuscular (IM) injection. Other routes are not studied and should not be used.
Initial/Maintenance Dose	The standard starting dose is 40 mg. Maintenance doses are typically 20 mg or 40 mg.
Frequency & Limit	Doses are administered every 6 to 12 hours as needed. The total amount must not exceed 80 mg in a 24-hour period.
Preparation Requirements	The powder must be reconstituted with an approved solvent, such as 0.9% sodium chloride solution. The solution should not be mixed with incompatible IV fluids, such as certain dextrose combinations, to prevent precipitation.

Duration and Adjustments

Dynastat is intended for short-term treatment of acute pain, with clinical experience generally limited to a duration of three days. Patients are transitioned to an appropriate oral analgesic as soon as clinically feasible.

Specific dose reductions are mandatory for certain patient populations. Older adults weighing less than 50 kg and patients with moderate hepatic impairment must initiate treatment at the lowest recommended dose (20 mg) and have a reduced maximum daily limit of 40 mg. The medicine is not recommended for pediatric patients as its use is not established in that age group.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dynastat

Evidence for Use in Acute Postoperative Pain

The primary research for Dynastat (Parecoxib) has centered on how it was studied for conditions associated with acute or disruptive episodes that follow surgery. This core evidence is derived from a large number of short-term, randomized controlled trials (RCTs), supported by systematic reviews and meta-analyses. In these trials, Parecoxib was studied for its use against both a harmless placebo injection and against other standard pain medications. Researchers monitored outcomes related to physical discomfort, primarily using standardized scales to measure symptom intensity at rest and during movement.

Research in Specific Surgical Contexts

Research has explored how the medicine was evaluated in specific surgical areas to understand the consistency of findings across different types of operations. Studies explored the administration of the medicine in patients undergoing orthopedic surgeries (like joint replacements), gynecological procedures, and certain types of general surgery. The findings describe patterns observed in the studies where research reported measurements on pain scores that differed between the Parecoxib and placebo groups across various post-surgical settings. Additionally, supplemental opioid medication use was associated with patterns that were measured differently in patients receiving Parecoxib.

Duration of Evidence and Follow-up Periods

The evidence largely stems from trials assessing short-term or episodic symptom patterns. The vast majority of the evidence available to regulators is concentrated on the immediate recovery period, with follow-up durations being limited to about 24 to 72 hours post-administration. Long-term patterns of change are not fully established, and evidence contributes to understanding symptom patterns only within the narrow, short timeframe of acute pain episodes.

Gaps and Ongoing Uncertainty in the Research

The research base provides evidence for the studied indication, but highlights specific areas where more information is needed. The certainty remains low in areas outside of the medication's approved short-term use. For instance, data regarding measured outcomes in children under 18 years of age are not fully established, as clinical trials were not conducted in this population. It is important to understand that research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Dynastat (FAQ)

Q: How quickly does Dynastat usually start to work?

According to official regulatory documents, the onset of pain relief usually begins within 7 to 14 minutes after the injection is given. The medicine’s effect generally reaches its peak within the first 2 hours of administration.

Q: What is the difference between Dynastat and other pain relief injections?

Dynastat is classified as a selective Cyclooxygenase-2 ( COX-2) inhibitor, which is a specific type of Non-Steroidal Anti-Inflammatory Drug (NSAID). Official information categorizes it as a non-narcotic analgesic used for short-term injectable pain relief following surgery.

Q: Does Dynastat cause drowsiness or affect my ability to drive?

Regulatory patient information states that this medicine may cause side effects such as dizziness or tiredness. Patients are cautioned against driving or operating machinery if these effects are experienced.

Q: Does Dynastat affect blood pressure or heart rate?

Official product information lists a change in blood pressure (either an increase or decrease) as a possible side effect. Information regarding existing cardiovascular conditions is important for the healthcare provider’s review.

Q: Is there any research evidence on Dynastat's use in older adults?

Yes, official documents specifically address the use of Dynastat in older adults. They note that for patients weighing less than 50 kg, dose adjustment may be required.

Q: Can Dynastat be used during pregnancy or while breastfeeding?

Official regulatory guidance states that Dynastat is contraindicated during the last three months of pregnancy. It is also contraindicated for women who are breastfeeding.

Q: Does official evidence suggest Dynastat helps reduce swelling?

The medicine works by reducing the production of prostaglandins, which are substances involved in inflammation and pain. While it targets inflammation, official safety information also notes that fluid retention and swelling ( oedema) have been reported as potential side effects.

Q: Can Dynastat be administered at home by a non-professional?

Dynastat is administered only as an intravenous ( IV) or intramuscular ( IM) injection. The required preparation and injection techniques are typically reserved for administration by trained healthcare professionals within a clinical setting.

Q: Is Dynastat considered a narcotic or opioid pain reliever?

No. Official classification identifies Dynastat as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a non-narcotic analgesic.

Q: Are there specific symptoms that mean I should stop treatment?

Official documents list certain symptoms that require immediate discontinuation and medical review. These include a severe allergic reaction, a skin rash, blistering, or signs of bleeding such as passing a black or bloody stool.

Q: Is Dynastat commonly used for pain relief after dental surgery?

Clinical studies reviewed by regulatory agencies included patients who had undergone a variety of surgical procedures, including dental surgery, to study the patterns of pain relief following surgery.

Q: How does Dynastat compare to ketorolac in official documents?

Official regulatory reviews indicate that Dynastat was studied in comparison to other painkillers, including ketorac, as part of the clinical trials for post-operative pain management.

Q: What are the signs of an overdose with Dynastat?

Signs of receiving too much Dynastat that have been reported include feeling tired, drowsy, feeling sick, and experiencing stomach pains or other abdominal issues.

Q: Does Dynastat have any known effect on mood?

Side effects listed in the product information that affect the nervous system include feeling agitated or having difficulty sleeping. Any changes observed should be reviewed by a healthcare provider.

Q: Is it possible for Dynastat to mask a serious underlying infection?

Official warnings state that, as an anti-inflammatory medicine, Dynastat may mask fever and other signs of inflammation. This may make it more difficult to detect an infection in a patient.

Q: Does Dynastat interact with alcohol?

Official safety information recommends that factors such as smoking or alcohol consumption be discussed with the healthcare provider prior to administration.

How should Dynastat be stored and disposed of?

Storage and Disposal of Dynastat (Parecoxib Sodium)

Official regulatory information for Dynastat, a lyophilized powder for injection, details distinct storage rules for the powder and the solution.

Storage Requirements

Product Form	Temperature / Protection	Stability Constraints
Unreconstituted Powder	Store at 25°C (77°F) with permitted excursions; must be protected from light (US labeling).	Does not require special storage conditions prior to mixing (EU labeling).
Reconstituted Solution	Must not be refrigerated or frozen. Store at 25°C.	Chemical stability is demonstrated for up to 24 hours at 25°C. For microbiological concerns, the solution should be used immediately or within 12 hours at 25°C if not prepared aseptically.

Child Safety and Disposal

Dynastat must be kept out of the sight and reach of children.

Disposal instructions state that unused product and waste material must be handled in accordance with local requirements. Care should be taken to avoid environmental release when discarding the waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.